A recent study has found that patients with epilepsy who use CBD products experienced better sleep and a higher quality of life in comparison with those who didn’t take CBD. The study, which was carried out in partnership with scientists at the Johns Hopkins University School of Medicine, was published in the “Epilepsy & Behavior” journal.
The study discovered that epilepsy patients who used cannabinoid products also experienced less psychiatric symptoms, including anxiety, used fewer prescription medications generally and tolerated medications prescribed for epilepsy better. They also reported decreased healthcare use in comparison with patients in the control group.
The authors of the study noted that while no substantial differences in seizure control were observed between patients who didn’t use CBD and those who did, both groups had individuals who hadn’t suffered seizures in the past month.
In their report, the researchers stated that their findings highlighted the need for controlled research to ascertain optimal CBD doses, product types and associated use of other medications that would minimize potential risks and maximize clinical benefit of the cannabinoid’s use.
The study centered on alternatives to Epidiolex, which is the pharmaceutical-grade CBD oil product that the FDA approved to treat specific types of epilepsy in 2018. The researchers explained that prescription CBD was a restricted medication, noting that insurance coverage was often limited to patients who suffered from the approved indications, which is why most patients who suffer from epilepsy chose to use alternative CBD products that are sold by commercial vendors as dietary supplements.
For the study, the researchers conducted an analysis of survey results from nearly 300 patients who suffer from epilepsy and admitted to using artisanal CBD products and about 140 patients who revealed that they did not use any marijuana products. The study’s participants were recruited using social media posts and patient registries provided by the Realm of Caring Foundation, with follow-up surveys being conducted on 190 participants.
Nearly 75% of the patients who took part in the survey were white, with more than 50% of them being female. About 90% of the participants revealed that they had no history of recreational or nonmedical marijuana use. Additionally, more than 90% of the participants reported epilepsy as their main condition, with the remainder revealing that they developed epilepsy related to sleep disorders, neuropsychiatric or autoimmune conditions, cancer and other conditions.
The study was financed by a not-for-profit foundation devoted to CBD therapies, known as the Realm of Caring Foundation.
This study is yet another indication that people who use the CBD products made by cannabis companies such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) may obtain sme relief from certain symptoms that they suffer from.
NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
